• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Alaris remediation could cost BD up to $244M

November 18, 2020 By Chris Newmarker

BD-logo-newBecton Dickinson (NYSE:BDX) in its most recent fiscal year set aside $244 million to cover future product remediation costs, including the company’s work to fix its problematic Alaris infusion pumps.

The Franklin Lakes, N.J.–based company has had shipments of the pumps on hold since early this year, when FDA called for a comprehensive 510(k) submission to covers a host of software fixes needed after a Class I-level recall. Pumps are only going to health providers with an immediate medical need.

The company expects to submit the 510(k) in late Q2 or early Q3 (around spring 2021), CEO Thomas Polen said during a Nov. 5 earnings call.

Alaris problems have been a major challenge for BD, which is also grappling with the COVID-19 pandemic. In the quarter ended Sept. 30, the Alaris ship hold affected revenue by 240 basis points, Polen said on Nov. 5.

“The highest priority of the organization continues to be preparing for a comprehensive 510(k) filing obtaining clearance for Alaris and returning our market-leading infusion pump franchise to growth,” Polen said. “Over the last quarter, the team has made further progress and retired risk.”

Warnings meanwhile continue to go out about the pumps. The company last week warned about cybersecurity issues; the notice applied to BD’s Alaris PC unit, model 8015, versions 9.33.1 and earlier, as well as the Alaris systems manager, versions 4.33 and earlier.

A Field Safety Notice from BD, posted Nov. 13 in Germany, involved the Alaris GW and GW800 volumetric pumps and that BD is updating directions for ise to include additional warnings related to the use of non-dedicated/noncompatible administration sets to mitigate against unregulated flow during infusion.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls Tagged With: BD, Becton Dickinson

IN CASE YOU MISSED IT

  • BD stock up on Street-beating preliminary quarterly revenue numbers
  • Locate Bio lands FDA breakthrough nod for bone infection device
  • PerkinElmer to acquire Oxford Immunotec
  • Evonik buys polymers business from Durect Corp.
  • New Croatian notified body designated to European MDR

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS